Success Metrics

Clinical Success Rate
42.9%

Based on 3 completed trials

Completion Rate
43%(3/7)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
4(57%)

Phase Distribution

Ph phase_4
1
14%
Ph not_applicable
3
43%
Ph phase_3
3
43%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
1(14.3%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(3)
Terminated(4)

Detailed Status

Terminated4
Completed3

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
42.9%
Most Advanced
Phase 4

Trials by Phase

Phase 33 (42.9%)
Phase 41 (14.3%)
N/A3 (42.9%)

Trials by Status

terminated457%
completed343%

Recent Activity

0 active trials
Showing 5 of 7
terminatednot_applicable

A Trial to Reduce Adhesions Following a Primary Cesarean Section

NCT01819467
terminatedphase_4

Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy

NCT01632202
completednot_applicable

Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients

NCT01594385
terminatedphase_3

Seprafilm® for Prevention of Adhesions at Repeat Cesarean

NCT00697606
completedphase_3

Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus

NCT02168426
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01819467Not Applicable

A Trial to Reduce Adhesions Following a Primary Cesarean Section

Terminated
NCT01632202Phase 4

Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy

Terminated
NCT01594385Not Applicable

Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients

Completed
NCT00697606Phase 3

Seprafilm® for Prevention of Adhesions at Repeat Cesarean

Terminated
NCT02168426Phase 3

Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus

Completed
NCT01095367Not Applicable

Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer

Terminated
NCT00529412Phase 3

Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction

Completed

All 7 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
7